Literature DB >> 3141171

In vitro activity of azithromycin and erythromycin against organisms associated with bacterial vaginosis and chancroid.

B M Jones1, G R Kinghorn, B I Duerden.   

Abstract

The in vitro activity of the new macrolide azithromycin and erythromycin against Haemophilus ducreyi, Gardnerella vaginalis, Bacteroides spp. and Mobiluncus spp. was compared. Gardnerella vaginalis, Mobiluncus spp. and Haemophilus ducreyi were highly susceptible to both agents but azithromycin was more effective overall against all three groups of organisms. The activity of both antibiotics against Bacteroides spp. varied greatly, but azithromycin was again more active. Collectively, 62% of all Bacteroides strains were susceptible to erythromycin (MIC 1 mg/1) and 74% were susceptible to azithromycin.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3141171     DOI： 10.1007/bf01962614

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  9 in total

1.  Sheffield medium for cultivation of Haemophilus ducreyi.

Authors:  S Hafiz; M G McEntegart; G R Kinghorn
Journal:  Br J Vener Dis       Date:  1984-06

Review 2.  Gardnerella vaginalis-associated vaginitis--a 'new' sexually transmitted disease.

Authors:  B M Jones
Journal:  Med Lab Sci       Date:  1983-01

Review 3.  An overview of the diagnosis and treatment of Gardnerella vaginalis and Bacteroides associated vaginitis.

Authors:  B M Jones; G R Kinghorn; B I Duerden
Journal:  Eur J Clin Microbiol       Date:  1982-10       Impact factor: 3.267

4.  Antimicrobial susceptibility of comma-shaped bacteria isolated from the vagina.

Authors:  A Skarin; E Holst; P A Mårdh
Journal:  Scand J Infect Dis Suppl       Date:  1983

5.  Susceptibility of Haemophilus ducreyi to ampicillin and sulbactam in vitro.

Authors:  B M Jones; S Hafiz; B I Duerden
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

6.  In-vitro and in-vivo activity of metronidazole against Gardnerella vaginalis, Bacteroides spp. and Mobiluncus spp. in bacterial vaginosis.

Authors:  B M Jones; I Geary; A B Alawattegama; G R Kinghorn; B I Duerden
Journal:  J Antimicrob Chemother       Date:  1985-08       Impact factor: 5.790

7.  Characteristics of motile curved rods in vaginal secretions.

Authors:  M S Sprott; H R Ingham; R S Pattman; R L Eisenstadt; G R Short; H K Narang; P R Sisson; J B Selkon
Journal:  J Med Microbiol       Date:  1983-05       Impact factor: 2.472

8.  In vitro activity of seventeen antimicrobial agents against Gardnerella vaginalis.

Authors:  S Shanker; M Toohey; R Munro
Journal:  Eur J Clin Microbiol       Date:  1982-10       Impact factor: 3.267

9.  A scheme for the identification of clinical isolates of Gram-negative anaerobic bacilli by conventional bacteriological tests.

Authors:  B I Duerden; J G Collee; R Brown; A G Deacon; W P Holbrook
Journal:  J Med Microbiol       Date:  1980-05       Impact factor: 2.472
  9 in total
  8 in total

Review 1.  Spectrum of activity of azithromycin.

Authors:  J D Williams
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

2.  In vitro susceptibilities of isolates of Haemophilus ducreyi from Thailand and the United States to currently recommended and newer agents for treatment of chancroid.

Authors:  J S Knapp; A F Back; A F Babst; D Taylor; R J Rice
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

Review 3.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 4.  Gardnerella vaginalis: characteristics, clinical considerations, and controversies.

Authors:  B W Catlin
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

5.  Correlation between in vitro antimicrobial susceptibilities and beta-lactamase plasmid contents of isolates of Haemophilus ducreyi from the United States.

Authors:  M Motley; S K Sarafian; J S Knapp; A A Zaidi; G Schmid
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

6.  Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.

Authors:  H Renaudin; C Bébéar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

7.  Azithromycin-liposomes as a novel approach for localized therapy of cervicovaginal bacterial infections.

Authors:  Željka Vanić; Zora Rukavina; Suvi Manner; Adyary Fallarero; Lidija Uzelac; Marijeta Kralj; Daniela Amidžić Klarić; Anita Bogdanov; Tímea Raffai; Dezső Peter Virok; Jelena Filipović-Grčić; Nataša Škalko-Basnet
Journal:  Int J Nanomedicine       Date:  2019-07-30

Review 8.  On the pathway to better birth outcomes? A systematic review of azithromycin and curable sexually transmitted infections.

Authors:  R Matthew Chico; Berkin B Hack; Melanie J Newport; Enesia Ngulube; Daniel Chandramohan
Journal:  Expert Rev Anti Infect Ther       Date:  2013-11-06       Impact factor: 5.091
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.